{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T14:13:19Z","timestamp":1769609599574,"version":"3.49.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2010,8,26]],"date-time":"2010-08-26T00:00:00Z","timestamp":1282780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100014489","name":"Johnson & Johnson Pharmaceutical Research & Development","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014489","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose.<\/jats:title>\n                  <jats:p>To evaluate the effects of epoetin alfa on patient-reported outcomes (PROs) in patients with breast cancer receiving myelotoxic chemotherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods.<\/jats:title>\n                  <jats:p>Women with hemoglobin concentrations \u226412.0 g\/dl and an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0\u20133 were randomized 1:1 to receive epoetin alfa (10,000 IU 3 times weekly) or best standard care (BSC) during chemotherapy. The primary endpoint was the change from baseline in the total anemia subscale assessed by the Functional Assessment of Cancer Therapy\u2013Anemia (FACT-An) questionnaire after 12 weeks of treatment. The fatigue and nonfatigue subscales from the FACT-An, the Cancer Linear Analog Scale (CLAS), hemoglobin changes, ECOG PS score, tumor response, overall survival, and safety also were evaluated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>Of 223 patients randomized, 216 constituted the modified intent-to-treat population. Percentage changes in the total anemia subscale of the FACT-An were significantly different between epoetin alfa treatment (14.2%) and BSC (\u22120.5%; p = .002), favoring epoetin alfa; so were changes in the FACT-An fatigue subscale (epoetin alfa, 17.5%; BSC, \u22120.9%; p = .003) and nonfatigue subscale (epoetin alfa, 8.8%; BSC, 0.2%; p = .008). Similar results were observed with the CLAS. Hemoglobin concentrations &amp;gt;12 g\/dl were more common with epoetin alfa (62.0%) than with BSC (27.6%). Tumor response, ECOG PS score, 12-month survival rate, and the incidence of serious treatment-emergent adverse events were similar between groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion.<\/jats:title>\n                  <jats:p>Early intervention with epoetin alfa was well tolerated and improved anemia-related PROs in patients with breast cancer receiving myelotoxic chemotherapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2009-0279","type":"journal-article","created":{"date-parts":[[2010,8,27]],"date-time":"2010-08-27T01:44:36Z","timestamp":1282873476000},"page":"935-943","source":"Crossref","is-referenced-by-count":25,"title":["Epoetin Alfa Improves Anemia and Anemia-Related, Patient-Reported Outcomes in Patients with Breast Cancer Receiving Myelotoxic Chemotherapy: Results of a European, Multicenter, Randomized, Controlled Trial"],"prefix":"10.1093","volume":"15","author":[{"given":"Paolo","family":"Pronzato","sequence":"first","affiliation":[{"name":"a Oncologia Medica, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy"}]},{"given":"Enrico","family":"Cortesi","sequence":"additional","affiliation":[{"name":"b Universit\u00e0 degli Studi, Rome, Italy"}]},{"given":"Carin C.","family":"Rijt","sequence":"additional","affiliation":[{"name":"c Erasmus MC, Daniel den Hoed Oncological Center, Rotterdam, The Netherlands"}]},{"given":"Alain","family":"Bols","sequence":"additional","affiliation":[{"name":"d A.Z. St. Jan, Brugge, Belgium"}]},{"given":"Jos\u00e9 A.","family":"Moreno-Nogueira","sequence":"additional","affiliation":[{"name":"e Servicio de Oncologia, Hospital Virgen del Rocio, Seville, Spain"}]},{"given":"Carlos Freire","family":"Oliveira","sequence":"additional","affiliation":[{"name":"f Hospitais da Universidade de Coimbra, Coimbra, Portugal"}]},{"given":"Peter","family":"Barrett-Lee","sequence":"additional","affiliation":[{"name":"g Academic Breast Oncology Unit, Velindre Hosp, Cardiff, United Kingdom"}]},{"given":"Peter J.","family":"Ostler","sequence":"additional","affiliation":[{"name":"h Department of Oncology, Mount Vernon Hospital, Northwood, Luton, United Kingdom"}]},{"given":"Ricardo","family":"Rosso","sequence":"additional","affiliation":[{"name":"i Scientific Direction, National Institute for Cancer Research, Genova, Italy"}]},{"name":"EPO-INT-47 Study Group","sequence":"additional","affiliation":[]}],"member":"286","published-online":{"date-parts":[[2010,8,26]]},"reference":[{"key":"2021122207520148900_R1","volume-title":"Overview: Breast Cancer","author":"American Cancer Society"},{"key":"2021122207520148900_R2","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.ejca.2004.06.019","article-title":"The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients","volume":"40","author":"Ludwig","year":"2004","journal-title":"Eur J Cancer"},{"key":"2021122207520148900_R3","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.ejca.2009.02.003","article-title":"Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: Findings from the Anaemia Cancer Treatment (ACT) study","volume":"45","author":"Ludwig","year":"2009","journal-title":"Eur J Cancer"},{"issue":"suppl 2","key":"2021122207520148900_R4","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0959-8049(05)80281-3","article-title":"Erythropoietin for anaemia in cancer patients","volume":"29A","author":"Abels","year":"1993","journal-title":"Eur J Cancer"},{"key":"2021122207520148900_R5","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2001.19.11.2865","article-title":"Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial","volume":"19","author":"Littlewood","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122207520148900_R6","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1200\/JCO.2004.10.020","article-title":"Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122207520148900_R7","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1200\/JCO.1997.15.3.1218","article-title":"Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group","volume":"15","author":"Glaspy","year":"1997","journal-title":"J Clin Oncol"},{"key":"2021122207520148900_R8","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.1998.16.10.3412","article-title":"Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. Procrit Study Group","volume":"16","author":"Demetri","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021122207520148900_R9","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2001.19.11.2875","article-title":"Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing","volume":"19","author":"Gabrilove","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122207520148900_R10","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0885-3924(02)00529-8","article-title":"Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales","volume":"24","author":"Cella","year":"2002","journal-title":"J Pain Symptom Manage"},{"key":"2021122207520148900_R11","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1200\/JCO.2004.12.027","article-title":"Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy","volume":"23","author":"Chang","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122207520148900_R12","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(03)14567-9","article-title":"Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial","volume":"362","author":"Henke","year":"2003","journal-title":"Lancet"},{"key":"2021122207520148900_R13","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1200\/JCO.2005.06.150","article-title":"Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study","volume":"23","author":"Leyland-Jones","year":"2005","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"2021122207520148900_R14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1359-6349(07)70099-X","article-title":"Randomized study of the importance of novel erythropoiesis stimulating protein (Aranesp\u00ae) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC): The Danish Head and Neck Cancer Group (DAHANCA 10) randomized trial","volume":"5","author":"Overgaard","year":"2007","journal-title":"Eur J Cancer"},{"issue":"20 suppl","key":"2021122207520148900_R15","first-page":"20s","article-title":"The impact of epoetin-alpha on anemia, red blood cell (RBC) transfusions, and survival in breast cancer patients (pts) treated with dose-dense sequential chemotherapy: Mature results of an AGO phase III study (ETC trial) [abstract 569]","volume":"25","author":"Moebus","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122207520148900_R16","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1200\/JCO.2007.11.5378","article-title":"Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and\/or taxane-based chemotherapy: Results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study","volume":"26","author":"Aapro","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10 suppl","key":"2021122207520148900_R17","first-page":"10s","article-title":"PREPARE trial. A randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF with a standard dosed epirubicin\/cyclophosphamide followed by paclitaxel {+\/-} darbepoetin alfa in primary breast cancer: A preplanned interim analysis of efficacy at surgery [abstract 517]","volume":"26","author":"Untch","year":"2008","journal-title":"J Clin Oncol"},{"issue":"suppl 10","key":"2021122207520148900_R18","first-page":"125","article-title":"The effects of anemia and anemia treatment on the quality of life of people with cancer","volume":"16","author":"Cella","year":"2002","journal-title":"Oncology (Williston Park)"},{"key":"2021122207520148900_R19","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/annonc\/mdh235","article-title":"The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: Results from five randomized clinical trials","volume":"15","author":"Cella","year":"2004","journal-title":"Ann Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2009-0279","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2009-0279","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/15\/9\/935\/41843826\/oncolo_15_9_935.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/15\/9\/935\/41843826\/oncolo_15_9_935.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T11:19:33Z","timestamp":1640171973000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/15\/9\/935\/6399505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,26]]},"references-count":19,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2010,8,26]]},"published-print":{"date-parts":[[2010,9,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2009-0279","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2010,9,1]]},"published":{"date-parts":[[2010,8,26]]}}}